HER2 Receptor Antagonist

DrugDrug NameDrug Indication
DB00072TrastuzumabIndicated for treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2. The intravenous powder for solution, OGIVRI, is approved in Canada for early breast cancer, metastatic breast cancer, and gastric cancer, provided these cancers overexpress HER2[L6214].
DB06366PertuzumabPertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.